Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia

Takehiko Mori, Yasushi Onishi, Yukiyasu Ozawa, Chiaki Kato, Tatsuyuki Kai, Yoshinobu Kanda, Mineo Kurokawa, Masatsugu Tanaka, Takashi Ashida, Yasushi Sawayama, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Hirohito Yamazaki

Research output: Contribution to journalArticle

Abstract

Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) for hepatitis-associated aplastic anemia have not been fully evaluated. In the present study, the outcomes of 37 adult patients with hepatitis-associated aplastic anemia who underwent allogeneic HSCT were retrospectively analyzed using the registry database of Japan Society for Hematopoietic Cell Transplantation. The median age of the patients was 24 years (range, 16–61). The median period between diagnosis of hepatitis-associated aplastic anemia and HSCT was 6.0 months (range, 0.5–430.8). Stem cell sources were bone marrow (N = 19) or peripheral blood stem cells (N = 5) from an HLA-identical sibling or bone marrow (N = 11) and cord blood (N = 2) from an unrelated donor. The majority of conditioning regimens were fludarabine-based or high-dose cyclophosphamide-based. In all but 2 cases of early death, neutrophil engraftment was achieved. At the time of analysis, 32 patients were alive, with a median follow-up of 54.1 months. Five-year overall and failure-free survival rates were 86.0% (95% CI, 69.4–93.9%) and 75.0% (95% CI, 57.4–86.2%), respectively. Despite the heterogeneity in transplant procedures in a small number of patients, these results suggest that allogeneic HSCT is safe for use in hepatitis-associated aplastic anemia with a low rate of transplant-related mortality.

Original languageEnglish
JournalInternational journal of hematology
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Aplastic Anemia
Hematopoietic Stem Cell Transplantation
Hepatitis
Bone Marrow
Transplants
Unrelated Donors
Cell Transplantation
Fetal Blood
Cyclophosphamide
Registries
Siblings
Japan
Neutrophils
Stem Cells
Survival Rate
Databases
Mortality

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Conditioning
  • Engraftment
  • Hepatitis-associated aplastic anemia
  • Transplant-related mortality

ASJC Scopus subject areas

  • Hematology

Cite this

Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia. / Mori, Takehiko; Onishi, Yasushi; Ozawa, Yukiyasu; Kato, Chiaki; Kai, Tatsuyuki; Kanda, Yoshinobu; Kurokawa, Mineo; Tanaka, Masatsugu; Ashida, Takashi; Sawayama, Yasushi; Fukuda, Takahiro; Ichinohe, Tatsuo; Atsuta, Yoshiko; Yamazaki, Hirohito.

In: International journal of hematology, 01.01.2019.

Research output: Contribution to journalArticle

Mori, T, Onishi, Y, Ozawa, Y, Kato, C, Kai, T, Kanda, Y, Kurokawa, M, Tanaka, M, Ashida, T, Sawayama, Y, Fukuda, T, Ichinohe, T, Atsuta, Y & Yamazaki, H 2019, 'Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia', International journal of hematology. https://doi.org/10.1007/s12185-019-02644-8
Mori, Takehiko ; Onishi, Yasushi ; Ozawa, Yukiyasu ; Kato, Chiaki ; Kai, Tatsuyuki ; Kanda, Yoshinobu ; Kurokawa, Mineo ; Tanaka, Masatsugu ; Ashida, Takashi ; Sawayama, Yasushi ; Fukuda, Takahiro ; Ichinohe, Tatsuo ; Atsuta, Yoshiko ; Yamazaki, Hirohito. / Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia. In: International journal of hematology. 2019.
@article{afa3d5ba67c84c1d97d99444fba3e741,
title = "Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia",
abstract = "Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) for hepatitis-associated aplastic anemia have not been fully evaluated. In the present study, the outcomes of 37 adult patients with hepatitis-associated aplastic anemia who underwent allogeneic HSCT were retrospectively analyzed using the registry database of Japan Society for Hematopoietic Cell Transplantation. The median age of the patients was 24 years (range, 16–61). The median period between diagnosis of hepatitis-associated aplastic anemia and HSCT was 6.0 months (range, 0.5–430.8). Stem cell sources were bone marrow (N = 19) or peripheral blood stem cells (N = 5) from an HLA-identical sibling or bone marrow (N = 11) and cord blood (N = 2) from an unrelated donor. The majority of conditioning regimens were fludarabine-based or high-dose cyclophosphamide-based. In all but 2 cases of early death, neutrophil engraftment was achieved. At the time of analysis, 32 patients were alive, with a median follow-up of 54.1 months. Five-year overall and failure-free survival rates were 86.0{\%} (95{\%} CI, 69.4–93.9{\%}) and 75.0{\%} (95{\%} CI, 57.4–86.2{\%}), respectively. Despite the heterogeneity in transplant procedures in a small number of patients, these results suggest that allogeneic HSCT is safe for use in hepatitis-associated aplastic anemia with a low rate of transplant-related mortality.",
keywords = "Allogeneic hematopoietic stem cell transplantation, Conditioning, Engraftment, Hepatitis-associated aplastic anemia, Transplant-related mortality",
author = "Takehiko Mori and Yasushi Onishi and Yukiyasu Ozawa and Chiaki Kato and Tatsuyuki Kai and Yoshinobu Kanda and Mineo Kurokawa and Masatsugu Tanaka and Takashi Ashida and Yasushi Sawayama and Takahiro Fukuda and Tatsuo Ichinohe and Yoshiko Atsuta and Hirohito Yamazaki",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/s12185-019-02644-8",
language = "English",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",

}

TY - JOUR

T1 - Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with hepatitis-associated aplastic anemia

AU - Mori, Takehiko

AU - Onishi, Yasushi

AU - Ozawa, Yukiyasu

AU - Kato, Chiaki

AU - Kai, Tatsuyuki

AU - Kanda, Yoshinobu

AU - Kurokawa, Mineo

AU - Tanaka, Masatsugu

AU - Ashida, Takashi

AU - Sawayama, Yasushi

AU - Fukuda, Takahiro

AU - Ichinohe, Tatsuo

AU - Atsuta, Yoshiko

AU - Yamazaki, Hirohito

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) for hepatitis-associated aplastic anemia have not been fully evaluated. In the present study, the outcomes of 37 adult patients with hepatitis-associated aplastic anemia who underwent allogeneic HSCT were retrospectively analyzed using the registry database of Japan Society for Hematopoietic Cell Transplantation. The median age of the patients was 24 years (range, 16–61). The median period between diagnosis of hepatitis-associated aplastic anemia and HSCT was 6.0 months (range, 0.5–430.8). Stem cell sources were bone marrow (N = 19) or peripheral blood stem cells (N = 5) from an HLA-identical sibling or bone marrow (N = 11) and cord blood (N = 2) from an unrelated donor. The majority of conditioning regimens were fludarabine-based or high-dose cyclophosphamide-based. In all but 2 cases of early death, neutrophil engraftment was achieved. At the time of analysis, 32 patients were alive, with a median follow-up of 54.1 months. Five-year overall and failure-free survival rates were 86.0% (95% CI, 69.4–93.9%) and 75.0% (95% CI, 57.4–86.2%), respectively. Despite the heterogeneity in transplant procedures in a small number of patients, these results suggest that allogeneic HSCT is safe for use in hepatitis-associated aplastic anemia with a low rate of transplant-related mortality.

AB - Outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) for hepatitis-associated aplastic anemia have not been fully evaluated. In the present study, the outcomes of 37 adult patients with hepatitis-associated aplastic anemia who underwent allogeneic HSCT were retrospectively analyzed using the registry database of Japan Society for Hematopoietic Cell Transplantation. The median age of the patients was 24 years (range, 16–61). The median period between diagnosis of hepatitis-associated aplastic anemia and HSCT was 6.0 months (range, 0.5–430.8). Stem cell sources were bone marrow (N = 19) or peripheral blood stem cells (N = 5) from an HLA-identical sibling or bone marrow (N = 11) and cord blood (N = 2) from an unrelated donor. The majority of conditioning regimens were fludarabine-based or high-dose cyclophosphamide-based. In all but 2 cases of early death, neutrophil engraftment was achieved. At the time of analysis, 32 patients were alive, with a median follow-up of 54.1 months. Five-year overall and failure-free survival rates were 86.0% (95% CI, 69.4–93.9%) and 75.0% (95% CI, 57.4–86.2%), respectively. Despite the heterogeneity in transplant procedures in a small number of patients, these results suggest that allogeneic HSCT is safe for use in hepatitis-associated aplastic anemia with a low rate of transplant-related mortality.

KW - Allogeneic hematopoietic stem cell transplantation

KW - Conditioning

KW - Engraftment

KW - Hepatitis-associated aplastic anemia

KW - Transplant-related mortality

UR - http://www.scopus.com/inward/record.url?scp=85064249893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064249893&partnerID=8YFLogxK

U2 - 10.1007/s12185-019-02644-8

DO - 10.1007/s12185-019-02644-8

M3 - Article

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

ER -